Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Acta Pharmaceutica Sinica B
; (6): 1315-1328, 2021.
Article
em En
| WPRIM
| ID: wpr-881201
Biblioteca responsável:
WPRO
ABSTRACT
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl
Texto completo:
1
Base de dados:
WPRIM
Idioma:
En
Revista:
Acta Pharmaceutica Sinica B
Ano de publicação:
2021
Tipo de documento:
Article